ReviewProbiotics and antimicrobial proteins2026
Beyond Antibiotics: Harnessing Bacteriotherapy to Heal Chronic Lymphatic Filariasis Wounds.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rising incidence of antibiotic-resistant bacteria such as multidrug-resistant Staphylococcus aureus (MRSA), drug-resistant E. coli, and Pseudomonas aeruginosa in chronic filarial wounds critically undermines the efficacy of antibiotics as standard therapies for chronic wounds in lymphatic filariasis. This challenge is intensified by widespread antibiotic misuse and self-medication among patients, complicating infection control and prolonging wound healing. As a result, there is a pressing need to adopt innovative treatment approaches. Bacteriotherapy represents a promising strategy for managing these chronic filarial wounds by effectively addressing persistent infections and inflammation that impede healing. This review comprehensively assesses current evidence to hypothesize the potential for advanced bacteriotherapeutic approaches in managing the complex morbidities of lymphatic filariasis, including lymphedema and its recurrent, complicated wounds. The findings highlight the potential of these innovative strategies to improve patient outcomes by targeting both filarial parasites and secondary bacterial infections. However, translating this promise into clinical practice requires further rigorous research, optimized treatment protocols, and tailored interventions suitable for endemic settings.
Indexed as
Identifiers
42611175What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.